Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Sees Large Decline in Short Interest

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) saw a significant decrease in short interest in the month of July. As of July 15th, there was short interest totaling 30,212 shares, a decrease of 59.3% from the June 30th total of 74,316 shares. Currently, 0.7% of the company’s shares are short sold. Based on an average trading volume of 110,675 shares, the short-interest ratio is presently 0.3 days.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Galmed Pharmaceuticals in a research note on Friday, July 17th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has an average rating of “Sell”.

Institutional Trading of Galmed Pharmaceuticals

An institutional investor recently bought a new stake in Galmed Pharmaceuticals stock. Two Sigma Investments LP bought a new stake in Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 21,200 shares of the biopharmaceutical company’s stock, valued at approximately $29,000. Two Sigma Investments LP owned 1.28% of Galmed Pharmaceuticals at the end of the most recent quarter. Institutional investors own 76.14% of the company’s stock.

Galmed Pharmaceuticals Stock Down 1.5%

Galmed Pharmaceuticals stock traded down $0.01 during mid-day trading on Wednesday, reaching $0.53. 46,947 shares of the company’s stock were exchanged, compared to its average volume of 1,663,336. Galmed Pharmaceuticals has a twelve month low of $0.41 and a twelve month high of $1.80. The company has a market cap of $2.88 million, a P/E ratio of -0.58 and a beta of 0.75. The company has a fifty day moving average of $0.58 and a 200-day moving average of $0.63.

Galmed Pharmaceuticals Company Profile

Galmed Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for metabolic and liver diseases. The company’s principal program centers on Aramchol, a synthetic fatty acid-bile acid conjugate designed to reduce liver fat accumulation and fibrosis in patients with nonalcoholic steatohepatitis (NASH). Galmed conducts translational research to validate its mechanism of action and advance its drug candidates through regulatory trials.

In addition to Aramchol, Galmed maintains a pipeline of complementary small-molecule compounds aimed at modulating lipid metabolism and inflammatory pathways implicated in chronic liver disorders.